TRIAL OF LIVE (PRIVATE) RECOMBINANT CANARYPOX ALVA-HIV VCP205 IN HIV

活体（私人）重组金丝雀痘 ALVA-HIV VCP205 在 HIV 中的试验

• 批准号: 6219471
• 负责人: Susan Buchbinder
• 金额: $ 0.06万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219471
• 关键词: AIDS education /prevention; AIDS therapy; AIDS vaccines; HIV infections; clinical research; clinical trial phase I; disease /disorder proneness /risk; high risk behavior /lifestyle; human subject; human therapy evaluation

The specific aims of the study are to: (1) evaluate the safety and describe the reactogenicity of two candidate HIV-1 vaccines administered simultaneously: ALVAC vCP205 and SF-2 rgp 120; (2) evaluate the humoral and cellular immunogenicity of this combination of vaccines; (3) compare reactogenicity and immunogenicity of this combination of two candidate vaccines in individuals at lower risk and higher risk of HIV-1 infection; (4) assess the feasibility of conducting preventive HIV-1 vaccine efficacy trials in high risk populations through the existing HIVNET structure, including the ability to recruit and retain a diverse cohort of high risk individuals into preventive HIV-1 vaccine trials; and (5) evaluate potential behavioral and social risks to study participants in preventive HIV-1 vaccine trials.

该研究的具体目的是：（1）评估安全性并描述同时施用的两种候选HIV-1疫苗的反应生成性：ALVAC VCP205和SF-2 RGP 120； （2）评估这种疫苗组合的体液和细胞免疫原性； （3）比较了两种候选疫苗在较低风险和HIV-1感染风险较高的个体中这种组合的反应生成性和免疫原性； （4）评估通过现有的HIVNET结构在高风险人群中进行预防性HIV-1疫苗疗效试验的可行性，包括招募和保留多种高风险个体的能力进入预防性HIV-1疫苗试验； （5）评估潜在的行为和社会风险，以研究预防性HIV-1疫苗试验中的参与者。